Recombinant Human Papillomavirus 9-Valent Vaccine (Escherichia coli) Covering HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58
The World’s Second 9-Valent HPV Vaccine
Approved in 2025, Cecolin 9 is a next-generation vaccine that builds on the proven global success of Cecolin, the bivalent HPV vaccine, and further expands protection across nine HPV types associated with cervical cancer and other HPV-related diseases.
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
China’s First HPV Vaccine and the World’s Second WHO-Prequalified Bivalent HPV Vaccine
Approved in 2019, Cecolin is China’s first domestically developed HPV vaccine and a milestone in expanding access to cervical cancer prevention. Since receiving WHO Prequalification in 2021, Cecolin has been approved in more than 24 countries and introduced into over 10 national immunization programs with more than 80 million doses distributed globally, helping make high-quality HPV protection more accessible worldwide.
Recombinant Hepatitis E vaccine (Escherichia coli）
The world’s first and only approved hepatitis E vaccine
Approved in 2011, Hecolin is the world’s first and only approved hepatitis E vaccine, marking a breakthrough in the prevention of hepatitis E. This milestone was recognized by Nature as a victory that could “help to deliver other vaccines for diseases overlooked in the West.”
闽公网安备 35020502000554号